This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • A 52-week (Plus Extension Until Commercialization)...
Clinical trial

A 52-week (Plus Extension Until Commercialization), Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI) at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab A

Read time: 2 mins
Last updated:1st May 2015
Identifier: NCT02595970
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest